What is hand-foot syndrome?
Hand-foot syndrome is a relatively common reaction, mainly of the palms and soles, following chemotherapy. It has many other names including -
- Acral erythema
- Burgdorf syndrome
- Chemotherapy-induced acral erythema
- Palmar plantar (palmoplantar) dysaesthesia
- Palmar plantar erythema
- Palmar plantar (palmoplantar) erythrodysaesthesia
- Plantar palmar erythroderma
- Toxic erythema of the palms and soles
It relates to the dose of chemotherapy drug – both the peak blood level and the cumulative dose appear to be important.
Who gets hand-foot syndrome?
Hand-foot syndrome always follows chemotherapy, with an overall frequency of about 2%. It can affect children and adults with a wide range of malignancies and has been reported following many chemotherapy drugs. It may also occur with EGFR / protein kinase inhibitors.
The most commonly used drug that frequently causes this reaction is 5-fluorouracil by infusion and its prodrug oral capecitabine.
However it is particularly common following pegylated liposomal doxorubicin, affecting approximately 50% with the first cycle but 75% by 9 cycles of the current recommended dose of 50mg/mm2.
Cytarabine, docetaxel, emitafur, hydroxyurea, methotrexate, tegafur and vinorelbin commonly trigger hand-foot syndrome. Blistering is said to be most common with cytarabine.
The list of drugs that cause hand-foot syndrome also includes cisplatin, cyclophosphamide, daunorubicin, doxorubicin, etoposide, floxuridin, irinotecan, 6-mercaptopurine, paclitaxel, sorafenib and 6-thioguanine.
Clinical features of hand-foot syndrome
Hand-foot syndrome usually first appears within days of commencing chemotherapy, although it may take several months and a number of chemotherapy cycles. The palms are always involved and less consistently the soles, fingers, toes, tops of feet and backs of hands. Uncommon sites include face, genital area, and sites affected by pressure or friction such as folds of skin and under tight clothing.
The first symptom is tingling, numbness, a feeling of tightness/stiffness or pain in the palms/fingers and sometimes a little later also the soles of feet/toes. This is followed 2-4 days later by bright redness of the palms and soles, which is symmetrical and sharply defined. Burning pain and swelling can develop. If severe it may blister and rarely ulcerate. Onycholysis (lifting of nails) is associated with severe reactions. In patients with dark skin, the skin may thicken and become darker in colour. It may interfere with daily activities such as holding objects, doing up buttons or walking. Cracking and peeling of the skin can occur. Wounds may heal less well.
If the chemotherapy is ceased then the reaction settles usually over 1-2 weeks (range 1-5 weeks), so it has recovered by the time the next cycle is due. Healing occurs without scarring unless there has been skin ulceration or necrosis (skin loss/death). However with each subsequent cycle of chemotherapy the reaction will appear more quickly, be more severe and will take longer to heal.
Although it is not life-threatening, hand-foot syndrome certainly affects quality of life and is often a dose-limiting side effect.
Grading hand-foot syndrome
A number of grading systems have been described to assess the severity of hand-foot syndrome. A recently devised grading follows.*
|Grade 1||No symptoms or only slight dysaesthesia, with mild redness|
|Grade 2||Dysaesthesia but no pain, severe redness and/or swelling|
|Grade 3||Dysaesthesia with pain, severe redness and/or swelling|
|Grade 4||Pain and impaired function in the activities of daily living, desquamation, blistering and ulceration|
*Von Moos R, Thuerlimann BJK, Aapro M et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. European Journal of Cancer 2008; 44: 781-790.
How is the diagnosis of hand-foot syndrome made?
The diagnosis is usually made clinically. However if a skin biopsy is taken it may show a variable degree of scattered individual skin cell death, inflammation at the junction of the epidermis and dermis and opening up of blood vessels.
Treatment of hand-foot syndrome
The only treatment shown to be of any benefit for hand-foot syndrome is ceasing the chemotherapy, waiting until the reaction has improved and recommencing therapy at a lower dose and/or frequency.
Patient education regarding this condition before starting chemotherapy is important so that patients report it promptly, especially when on chemotherapy drugs administered orally at home.
Use of a hand/foot moisturiser before starting chemotherapy is recommended. Avoiding mechanical trauma to hands and feet (and all body skin) such as friction, heat, pressure, irritants and adhesives may help limit the reaction. This includes wearing loose fitting comfortable clothing, which avoids tight pressure or rubbing.
Cooling of the hands and feet during chemotherapy administration has had variable success in preventing the reaction.
Once the reaction has developed, analgesics, cold compresses and elevation or cushioning of the affected parts may give some relief. Various treatments have been tried, usually on small numbers of patients, including topical and oral pyridoxine (vitamin B6), topical and oral corticosteroids, topical DMSO and topical vitamin E, with inconsistent responses.
Hand-foot syndrome is remarkable for its localization to the palms and soles. It has been proposed that the drug is excreted in the sweat from the eccrine sweat glands. This type of sweat gland is particularly numerous on palms and soles where they produce sweat continuously. The drug then concentrates in the skin and exerts its usual cytotoxic effect on the rapidly dividing skin cells.
Skin cells of the palms have been shown to divide more rapidly than those on the back, so they would be more susceptible to a chemotherapy drug. The enzyme that converts the prodrug capecitabine to the active drug 5-fluorouracil is particularly active in the palms. The skin of the palms and soles has a number of other unique features including its blood circulation, temperature and pressure effects which may also be relevant. The involvement of the palms more consistently than the soles may relate to activities of daily living.
- Hueso L, Sanmartin O, Nagore E et al. Chemotherapy-induced acral erythema: A clinical and histopathological study of 44 cases. Ann. Dermatol. Venereol. 2008; 135: 580-583. Medline.
- Milano G, Etienne-Grimaldi M-C, Mari M et al. Candidate mechanisms for capecitabine related hand-foot syndrome. Br. J. Clin. Pharmacol. 2008; 66: 88-95. Medline.
- Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE) - a literature review with commentary on experience in a cancer centre. Eur. J. Oncol. Nurs. 2007; 11: 238-246. Medline.
- Janusch M, Fischer M, Marsch WCh, Holzhausen H-J, Kegel T, Helmbold P. The hand-foot syndrome – a frequent secondary manifestation of antineoplastic chemotherapy. Eur. J. Dermatol. 2006; 16: 494-9. Medline.
- Von Moos R, Thuerlimann BJK, Aapro M et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. Eur. J. Cancer 2008; 44: 781-790. Medline.
On DermNet NZ:
- Chemotherapy induced toxicity
- Bullous drug eruptions
- Cutaneous side effects of EGFR and protein kinase inhibitors
Books about skin diseases:
See the DermNet NZ bookstore